- Alkyl continues to report strong growth; 1HFY20 revenue/EBITDA/PAT increased 26%/36%/99% YoY.
- Gross margins improved 3ppt YoY to 51.1% led by higher realizations for Acetonitrile and better product mix.
- Healthy cash generation led to debt reduction; net debt-equity improved to 0.2x.
Views: Capacity addition (debottlenecking existing/fresh additions) amid demand uptick and improving product mix (higher share of derivatives) should drive significant earnings growth in the next 3 years.
Current valuations (16x TTM earnings) are reasonable given favourable industry dynamics (duopolistic industry, huge import substitution and high fixed costs), healthy 25% pre-tax RoCE (FY19) and strong cash conversion (113% 1HFY20 CFO-EBITDA) to fund future capex.
Disclaimer: The above report is compiled from information available on public platforms. inChat team advises users to check with certified experts before taking any investment decisions.
Found this insight useful?
Please share with your friends and family as well. You can also subscribe to one of our channels listed at the bottom of this page.